OncoZenge AB (8LY) Price & Analysis

0 Followers

8LY Stock Chart & Stats

€0.59

-€0.02(-7.82%)

At close: Jan 08 4:00 PM EST

€0.59

-€0.02(-7.82%)

Day’s Range― - ―

52-Week Range€0.45 - €0.75

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€7.58M

Enterprise Value€79.68

Total Cash (Recent Filing)€935.00K

Total Debt (Recent Filing)€7.50M

Price to Earnings (P/E)―

Beta0.28

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.74

Shares Outstanding14,820,865

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)-139.70

Price to Sales (P/S)30.78

P/FCF Ratio-6.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.09

Revenue Forecast (FY)€924.04K

Bulls Say, Bears Say

Bulls Say

Focused Oncology Supportive-care ProductA focused product addressing oral pain in patients receiving cancer treatment gives OncoZenge a clearly defined clinical use case. If development and commercialization succeed, specialization may support targeted market access and partner interest.

Partnering-based Commercialization OptionalityThe potential to commercialize directly or license regional rights gives the company multiple routes to monetize BupiZenge™. A successful partner could provide development, regulatory and distribution capabilities that exceed its internal resources.

Positive Gross Profit In TTMPositive gross profit indicates that reported sales have generated some contribution before operating expenses. This provides an early commercial signal, although the benefit is currently immaterial and would need substantial scale to support the business.

Bears Say

Minimal And Sharply Declining RevenueVery limited and sharply declining revenue indicates that the company has not yet established a dependable commercial base. Without sustained product sales or licensing income, funding operations and validating the business model remain difficult.

Persistent Operating Losses And Cash BurnLarge losses and ongoing cash consumption show that operations are not self-funding. Continued development and commercialization will likely require external capital, creating financing dependence and potential dilution or additional borrowing.

Extremely Weak And Highly Leveraged Balance SheetA thin equity base relative to debt leaves little capacity to absorb setbacks or fund development. The shift from zero debt in 2021–2024 to meaningful debt in 2025–TTM materially increases solvency and refinancing risk.

OncoZenge AB News

OncoZenge’s BupiZenge Heads Into Phase III: What This Pain Study Means for Investors

OncoZenge AB ($DE:8LY) announced an update on their ongoing clinical study. The phase III trial “A Randomized, Open-label,...

2M ago

8LY

8LY FAQ

What was OncoZenge AB’s price range in the past 12 months?

OncoZenge AB lowest stock price was €0.45 and its highest was €0.75 in the past 12 months.

What is OncoZenge AB’s market cap?

OncoZenge AB’s market cap is €7.58M.

When is OncoZenge AB’s upcoming earnings report date?

OncoZenge AB’s upcoming earnings report date is Aug 27, 2026 which is yesterday.

How were OncoZenge AB’s earnings last quarter?

Currently, no data Available

Is OncoZenge AB overvalued?

According to Wall Street analysts OncoZenge AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoZenge AB pay dividends?

OncoZenge AB does not currently pay dividends.

What is OncoZenge AB’s EPS estimate?

OncoZenge AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoZenge AB have?

OncoZenge AB has 14,820,865 shares outstanding.

What happened to OncoZenge AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of OncoZenge AB?

Currently, no hedge funds are holding shares in DE:8LY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoZenge AB

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).